NASDAQ:TNDM

Tandem Diabetes Care Stock Forecast, Price & News

$92.06
+0.62 (+0.68 %)
(As of 04/16/2021 12:00 AM ET)
Add
Compare
Today's Range
$89.97
Now: $92.06
$92.37
50-Day Range
$81.28
MA: $88.10
$95.99
52-Week Range
$67.38
Now: $92.06
$123.74
Volume687,262 shs
Average Volume779,257 shs
Market Capitalization$5.76 billion
P/E RatioN/A
Dividend YieldN/A
Beta0.31
Tandem Diabetes Care, Inc., a medical device company, designs, develops, and commercializes various products for people with insulin-dependent diabetes in the United States. The company's flagship product is the t:slim X2 insulin delivery system, a pump platform that comprises t:slim X2 pump, its 300-unit disposable insulin cartridge, and an infusion set. It also provides t:slim X2 insulin with Basal-IQ and control IQ technology; t:slim X2 with G5 Integration; and Tandem Device Updater, a tool that allows users to update their pump's software. In addition, the company offers t:connect, a web-based data management application, which provides a visual way to display diabetes therapy management data from the pump, continuous glucose monitoring, and supported blood glucose meters for users, their caregivers, and their healthcare providers; and Sugarmate, a mobile app for people with diabetes who use insulin. Its products in development include t:sport insulin delivery system; and connected (mobile) health offerings. Tandem Diabetes Care, Inc. has a development and commercialization agreement with Dexcom, Inc. The company was formerly known as Phluid Inc. and changed its name to Tandem Diabetes Care, Inc. in January 2008. Tandem Diabetes Care, Inc. was incorporated in 2006 and is headquartered in San Diego, California.
Tandem Diabetes Care logo

Industry, Sector and Symbol

Industry Surgical & medical instruments
Sub-IndustryN/A
SectorMedical
Current SymbolNASDAQ:TNDM
CUSIPN/A
Phone858-366-6900
Employees1,500
Year FoundedN/A

Debt

Price-To-Earnings

Sales & Book Value

Annual Sales$362.30 million
Book Value$3.30 per share

Profitability

Net Income$-24,750,000.00

Miscellaneous

Market Cap$5.76 billion
Next Earnings Date5/5/2021 (Confirmed)
OptionableOptionable

Headlines

Tandem Diabetes Care (NASDAQ:TNDM) Trading Up 5.2%
April 15, 2021 |  americanbankingnews.com
Is Tandem Diabetes Care (TNDM) Stock a Buy For 2021?
March 1, 2021 |  finance.yahoo.com
Tandem Diabetes Care EPS beats by $0.10, beats on revenue
February 27, 2021 |  seekingalpha.com
Tandem Diabetes Surpasses 4Q Estimates; Shares Rise 4%
February 26, 2021 |  finance.yahoo.com
A Preview Of Tandem Diabetes Care's Earnings
February 23, 2021 |  finance.yahoo.com
See More Headlines

MarketRank

Overall MarketRank

1.63 out of 5 stars

Medical Sector

361st out of 2,024 stocks

Surgical & Medical Instruments Industry

35th out of 169 stocks

Analyst Opinion: 3.3Community Rank: 2.5Dividend Strength: 0.0Insider Behavior: 1.7Valuation: 0.6 5 -4 -3 -2 -1 -
$92.06
+0.62 (+0.68 %)
(As of 04/16/2021 12:00 AM ET)
30 days | 90 days | 365 days | Advanced Chart

Receive TNDM News and Ratings via Email

Sign-up to receive the latest news and ratings for TNDM and its competitors with MarketBeat's FREE daily newsletter.

speech bubbles
speech bubbles











Tandem Diabetes Care (NASDAQ:TNDM) Frequently Asked Questions

Is Tandem Diabetes Care a buy right now?

13 Wall Street analysts have issued "buy," "hold," and "sell" ratings for Tandem Diabetes Care in the last twelve months. There are currently 4 hold ratings and 9 buy ratings for the stock. The consensus among Wall Street analysts is that investors should "buy" Tandem Diabetes Care stock.
View analyst ratings for Tandem Diabetes Care
or view top-rated stocks.

What stocks does MarketBeat like better than Tandem Diabetes Care?

Wall Street analysts have given Tandem Diabetes Care a "Buy" rating, but there may be better short-term opportunities in the market. Some of MarketBeat's past winning trading ideas have resulted in 5-15% weekly gains. MarketBeat just released five new trading ideas, but Tandem Diabetes Care wasn't one of them. MarketBeat thinks these five stocks may be even better buys.
View MarketBeat's top stock picks here.

When is Tandem Diabetes Care's next earnings date?

Tandem Diabetes Care is scheduled to release its next quarterly earnings announcement on Wednesday, May 5th 2021.
View our earnings forecast for Tandem Diabetes Care
.

How can I listen to Tandem Diabetes Care's earnings call?

Tandem Diabetes Care will be holding an earnings conference call on Wednesday, May 5th at 12:00 AM Eastern. Interested parties can register for or listen to the call using this link or dial in at Not Available.

How were Tandem Diabetes Care's earnings last quarter?

Tandem Diabetes Care, Inc. (NASDAQ:TNDM) posted its quarterly earnings results on Tuesday, February, 23rd. The medical device company reported $0.22 EPS for the quarter, beating the consensus estimate of $0.12 by $0.10. The medical device company had revenue of $168.07 million for the quarter, compared to analysts' expectations of $141.13 million. Tandem Diabetes Care had a negative net margin of 11.10% and a negative trailing twelve-month return on equity of 10.98%.
View Tandem Diabetes Care's earnings history
.

How has Tandem Diabetes Care's stock price been impacted by COVID-19?

Tandem Diabetes Care's stock was trading at $66.33 on March 11th, 2020 when COVID-19 reached pandemic status according to the World Health Organization. Since then, TNDM shares have increased by 38.8% and is now trading at $92.06.
View which stocks have been most impacted by COVID-19
.

When did Tandem Diabetes Care's stock split? How did Tandem Diabetes Care's stock split work?

Shares of Tandem Diabetes Care reverse split on the morning of Tuesday, October 10th 2017. The 1-10 reverse split was announced on Monday, October 9th 2017. The number of shares owned by shareholders was adjusted after the closing bell on Monday, October 9th 2017. An investor that had 100 shares of Tandem Diabetes Care stock prior to the reverse split would have 10 shares after the split.

What guidance has Tandem Diabetes Care issued on next quarter's earnings?

Tandem Diabetes Care issued an update on its FY 2021 After-Hours earnings guidance on Wednesday, February, 24th. The company provided EPS guidance of for the period. The company issued revenue guidance of $600-615 million, compared to the consensus revenue estimate of $563.05 million.

What price target have analysts set for TNDM?

13 equities research analysts have issued 12-month target prices for Tandem Diabetes Care's stock. Their forecasts range from $75.00 to $150.00. On average, they anticipate Tandem Diabetes Care's stock price to reach $115.92 in the next year. This suggests a possible upside of 25.9% from the stock's current price.
View analysts' price targets for Tandem Diabetes Care
or view top-rated stocks among Wall Street analysts.

Who are Tandem Diabetes Care's key executives?

Tandem Diabetes Care's management team includes the following people:
  • Mr. John F. Sheridan, Pres, CEO & Director (Age 66, Pay $1.24M)
  • Ms. Leigh A. Vosseller, Exec. VP, CFO & Treasurer (Age 48, Pay $769.82k)
  • Ms. Susan M. Morrison, Exec. VP & Chief Admin. Officer (Age 42, Pay $768.61k)
  • Mr. David B. Berger, Exec. VP, Chief Bus. Operations & Compliance Officer and Corp. Sec. (Age 51, Pay $769.25k)
  • Mr. Brian B. Hansen, Exec. VP & Chief Commercial Officer (Age 53, Pay $778.26k)
  • Mr. Jim Leal, Sr. VP of Operations
  • Mr. Manuel Jaime, Sr. VP of Technology & Digital Health
  • Mr. Ross Sylvia, VP of Marketing
  • Ms. Elizabeth A. Gasser, Exec. VP of Strategy & Corp. Devel. (Age 45)
  • Mr. Tom Fox, Sr. VP of HR & Organizational Devel.

What is John Sheridan's approval rating as Tandem Diabetes Care's CEO?

11 employees have rated Tandem Diabetes Care CEO John Sheridan on Glassdoor.com. John Sheridan has an approval rating of 88% among Tandem Diabetes Care's employees.

Who are some of Tandem Diabetes Care's key competitors?

What other stocks do shareholders of Tandem Diabetes Care own?

Based on aggregate information from My MarketBeat watchlists, some companies that other Tandem Diabetes Care investors own include NVIDIA (NVDA), Advanced Micro Devices (AMD), Alibaba Group (BABA), Micron Technology (MU), DexCom (DXCM), Netflix (NFLX), Square (SQ), Roku (ROKU), Lululemon Athletica (LULU) and PayPal (PYPL).

What is Tandem Diabetes Care's stock symbol?

Tandem Diabetes Care trades on the NASDAQ under the ticker symbol "TNDM."

Who are Tandem Diabetes Care's major shareholders?

Tandem Diabetes Care's stock is owned by many different retail and institutional investors. Top institutional investors include Chicago Capital LLC (0.73%), Hodges Capital Management Inc. (0.03%) and GPS Wealth Strategies Group LLC (0.00%). Company insiders that own Tandem Diabetes Care stock include Brian B Hansen, Christopher J Twomey, David B Berger, Dick Allen, Douglas A Roeder, Edward L Cahill, Howard E Greene Jr, John F Sheridan, Kim D Blickenstaff, Leigh Vosseller, Rebecca B Robertson and Susan Morrison.
View institutional ownership trends for Tandem Diabetes Care
.

Which major investors are selling Tandem Diabetes Care stock?

TNDM stock was sold by a variety of institutional investors in the last quarter, including Hodges Capital Management Inc.. Company insiders that have sold Tandem Diabetes Care company stock in the last year include Brian B Hansen, Christopher J Twomey, David B Berger, Dick Allen, John F Sheridan, Kim D Blickenstaff, Leigh Vosseller, Rebecca B Robertson, and Susan Morrison.
View insider buying and selling activity for Tandem Diabetes Care
or view top insider-selling stocks.

Which major investors are buying Tandem Diabetes Care stock?

TNDM stock was purchased by a variety of institutional investors in the last quarter, including Chicago Capital LLC, and GPS Wealth Strategies Group LLC.
View insider buying and selling activity for Tandem Diabetes Care
or or view top insider-buying stocks.

How do I buy shares of Tandem Diabetes Care?

Shares of TNDM can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include WeBull, Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity, and Charles Schwab.
Compare Top Brokerages Here.

What is Tandem Diabetes Care's stock price today?

One share of TNDM stock can currently be purchased for approximately $92.06.

How much money does Tandem Diabetes Care make?

Tandem Diabetes Care has a market capitalization of $5.76 billion and generates $362.30 million in revenue each year. The medical device company earns $-24,750,000.00 in net income (profit) each year or ($0.22) on an earnings per share basis.

How many employees does Tandem Diabetes Care have?

Tandem Diabetes Care employs 1,500 workers across the globe.

What is Tandem Diabetes Care's official website?

The official website for Tandem Diabetes Care is www.tandemdiabetes.com.

Where are Tandem Diabetes Care's headquarters?

Tandem Diabetes Care is headquartered at 11075 ROSELLE STREET, San Diego CA, 92121.

How can I contact Tandem Diabetes Care?

Tandem Diabetes Care's mailing address is 11075 ROSELLE STREET, San Diego CA, 92121. The medical device company can be reached via phone at 858-366-6900 or via email at [email protected]


This page was last updated on 4/18/2021 by MarketBeat.com Staff
MarketBeat - Stock Market News and Research Tools logo

MarketBeat empowers individual investors to make better trading decisions by providing real-time financial data and objective market analysis. Whether you’re looking for analyst ratings, corporate buybacks, dividends, earnings, economic reports, financials, insider trades, IPOs, SEC filings or stock splits, MarketBeat has the objective information you need to analyze any stock. Learn more.

MarketBeat is accredited by the Better Business Bureau

© American Consumer News, LLC dba MarketBeat® 2010-2021. All rights reserved.
326 E 8th St #105, Sioux Falls, SD 57103 | U.S. Based Support Team at [email protected] | (844) 978-6257
MarketBeat does not provide personalized financial advice and does not issue recommendations or offers to buy stock or sell any security. Learn more.

Our Accessibility Statement | Terms of Service | Do Not Sell My Information

© 2021 Market data provided is at least 10-minutes delayed and hosted by Barchart Solutions. Information is provided 'as-is' and solely for informational purposes, not for trading purposes or advice, and is delayed. To see all exchange delays and terms of use please see disclaimer. Fundamental company data provided by Zacks Investment Research. As a bonus to opt-ing into our email newsletters, you will also get a free subscription to the Liberty Through Wealth e-newsletter. You can opt out at any time.